A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 4, 2012, Pages

  Martin, Ludmila Katherine ^a   Grecula, John ^a   Jia, Guang ^a   Wei, Lai ^a   Yang, Xiangyu ^a   Otterson, Gregory A ^b   Wu, Xin ^c   Harper, Erica ^c   Kefauver, Cheryl ^c   Zhou, Bing Sen ^d   Yen, Yun ^d   Bloomston, Mark ^a   Knopp, Michael ^a   Ivy, S Percy ^e   Grever, Michael ^a   Bekaii Saab, Tanios ^a  

^a Division of Surgical Oncology   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MAGNETIC RESONANCE IMAGING;

DOSE LIMITING TOXICITY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EVALUATION PROGRAM; LOCAL TUMOR PROGRESSIONS; MAXIMUM TOLERATED DOSE; METHODS AND MATERIALS; NATIONAL CANCER INSTITUTE; RIBONUCLEOTIDE REDUCTASE;

RADIOTHERAPY;

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ALANINE AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE 1; RIBONUCLEOTIDE REDUCTASE 2; UNCLASSIFIED DRUG; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; PYRIDINE DERIVATIVE; RADIOSENSITIZING AGENT; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; RRM1 PROTEIN, HUMAN; THIOSEMICARBAZONE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; BLOOD; DISEASE COURSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; RADIATION DOSE;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; PYRIDINES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; THIOSEMICARBAZONES; TUMOR SUPPRESSOR PROTEINS;

EID: 84872037769     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.06.003     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Cohen SJ, Pinover WH, Watson JC, et al. Pancreatic cancer. Curr Treat Options Oncol 2000; 1:375-386.
3. Kim HJ, Czischke K, Brennan MF, et al. Does neoadjuvant chemo-radiation downstage locally advanced pancreatic cancer? J Gastro-intest Surg 2002; 6:763-769.
4. Souglakos J, Boukovinas I, Taron M, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 2008; 98:1710-1715.
5. Kuo ML, Hwang HS, Sosnay PR, et al. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. Cancer J 2003; 9:277-285.
6. Cory JG. Ribonucleotide reductase as a chemotherapeutic target. Adv Enzyme Regul 1988; 27:437-455.
7. Zhu L, Zhou B, Chen X, et al. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonu-cleotide reductase. Biochem Pharmacol 2009; 78:1178-1185.
8. Barker CA, Burgan WE, Carter DJ, et al. In vitro and in vivo radio-sensitization induced by the ribonucleotide reductase inhibitor triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin Cancer Res 2006; 12:2912-2918.
9. Kunos CA, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res 2010; 174:574-581.
10. Feun L, Modiano M, Lee K, et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 2002; 50:223-229.
11. Kunos CA, Chiu SM, Pink J, et al. Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res 2009; 172:666-676.
12. Murren J, Modiano M, Clairmont C, et al. Phase I and pharmacoki-netic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 2003; 9:4092-4100.
13. Wadler S, Makower D, Clairmont C, et al. Phase I and pharma-cokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2- carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004; 22: 1553-1563.
14. Kunos CA, Waggoner S, von Gruenigen V, et al. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res 2010; 16:1298-1306.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
16. Yang X, Liang J, Heverhagen JT, et al. Improving the pharmacokinetic parameter measurement in dynamic contrast-enhanced MRI by use of the arterial input function: theory and clinical application. Magn Reson Med 2008; 59:1448-1456.
17. Zhou B, Phan V, Liu X, et al. Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immu-nohistochemistry study of human cancer tissues. Hybridoma (Larchmt) 2006; 25:264-270.
18. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Pre-operative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7:e1000267.
19. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25:326-331.
20. Sigmond J, Kamphuis JA, Laan AC, et al. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem Pharmacol 2007; 73:1548-1557.